CV SciencesCVSI FCF Margin % is 3.07% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 958 Drug Manufacturers companies, CV Sciences ranks worse than 62.53% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CV Sciences's Free Cash Flow for the
three
months ended in Mar. 2026 was $0.10 Mil. CV Sciences's Revenue for the
three
months ended in Mar. 2026 was $3.20 Mil. Therefore, CV Sciences's FCF Margin % for the quarter that ended in Mar. 2026 was 3.07%.
The historical rank and industry rank for CV Sciences's FCF Margin % or its related term are showing as below:
CVSI'
s FCF Margin % Range Over the Past 10 Years
Min: -37.51 Med: -5.94 Max: 23.45
Current: -2.22
During the past 13 years, the highest FCF Margin % of CV Sciences was 23.45%. The lowest was -37.51%. And the median was -5.94%.
CVSI's FCF Margin % is ranked worse than 62.53% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs CVSI: -2.22
CV Sciences FCF Margin % Related Terms
CV Sciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for CV Sciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CV Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CV Sciences FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CV Sciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where CV Sciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CV Sciences (CVSI) has a FCF Margin % of 3.07% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CV Sciences and its competitors. According to the industry distribution chart, CV Sciences ranks #599 out of 958 companies in the Drug Manufacturers industry, placing it in the top 62.5%.
Is CV Sciences' FCF Margin % too high?
CV Sciences' current FCF Margin % is 3.07%. The Drug Manufacturers industry median FCF Margin % is 2.45. CV Sciences' value of 3.07% is 25.6% above this industry median. Based on the distribution chart, CV Sciences ranks #599 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does CV Sciences' FCF Margin % compare to INM and GELS?
According to the Drug Manufacturers industry distribution chart, CV Sciences ranks #599 out of 958 companies for FCF Margin %. This places CV Sciences in the lower half of its industry. The industry median FCF Margin % is 2.45. CV Sciences' value of 3.07% is 25.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CV Sciences's current FCF Margin % of 3.07% is 25.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CV Sciences and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CV Sciences's current FCF Margin % is 3.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CV Sciences stock overvalued right now?
Based on GuruFocus' analysis, CV Sciences (CVSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 26.7% below its estimated fair value. The current FCF Margin % is 3.07% and 25.6% above the Drug Manufacturers industry median of 2.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For CV Sciences (CVSI), the current FCF Margin % is 3.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CV Sciences Inc is a consumer wellness company specializing in nutraceuticals and plant-based foods products. It develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol. The company sells its products under tradenames, such as +PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox. The company's products are sold in a variety of market sectors, including nutraceutical, beauty care, and specialty foods. The company has one operating segment, which is the business of hemp-based CBD wellness products. Geographically, all of the company's revenue is generated from United States. The company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVSI has been successfully added to your 